Immunotherapy plus stereotactic body radiation therapy or whole-brain radiation therapy in brain metastases.
Saber A AminMichael BaineChi LinPublished in: Immunotherapy (2023)
Aim: To investigate the association of stereotactic radiation therapy (SRT) or whole-brain radiation therapy (WBRT) plus immunotherapy with the overall survival (OS) of cancer patients with brain metastases (BMs) regardless of the primary cancer. Patients & methods: Patients diagnosed with BMs were identified from the National Cancer Database. Results: A total of 34,286 patients were included. SRT plus immunotherapy was associated with improved OS compared with SRT without immunotherapy (hazard ratio: 0.774; 95% CI: 0.687-0.872; p < 0.001), and WBRT plus immunotherapy was associated with improved OS compared with WBRT without immunotherapy (hazard ratio: 0.724; 95% CI; 0.673-0.779; p < 0.001). Conclusion: SRT plus immunotherapy was associated with improved OS compared with SRT. WBRT plus immunotherapy was associated with improved OS compared with WBRT in cancer patients who had BMs at the time of primary cancer diagnosis.
Keyphrases
- brain metastases
- radiation therapy
- small cell lung cancer
- end stage renal disease
- papillary thyroid
- newly diagnosed
- ejection fraction
- chronic kidney disease
- squamous cell
- prognostic factors
- emergency department
- white matter
- locally advanced
- resting state
- functional connectivity
- patient reported
- multiple sclerosis
- brain injury
- subarachnoid hemorrhage
- electronic health record